We sent email to our subscribers on August 29th with our new break-out pick: Advaxis (ADXS).
Congratulations to all who followed our alert – ADXS‘s share price doubled in less than 2 weeks!
Email:
ADXS Breaks Resistance and Set To Rally
Advaxis made a strong move on Thursday, despite the typical quiet week of trading before Labor Day weekend, and the cyclical return of liquidity in September. This, coupled with above-average volume (greatest volume day since May), suggests ADXS may be ready for a bigger move.
Last year, we wrote to you advising you watch Sunshine Heart (SSH). Sunshine Heart was a newly listed medical device company that soared from $3.50 (where we recommended it) to over $16. Sunshine Heart had a tiny 5-6M share float, which propelled the move and attracted traders.
ADXS has an even smaller float. Likely in the neighborhood of 2M.
ADXS just announced a new CEO was appointed, which may explain renewed excitement among investors. The new CEO helped sell Imclone Systems for $6.5 Billion to Eli Lilly in 2008. He joined Advaxis to prove this technology is worth billions, as some of the Company’s peers are valued.
At a $15M market cap, ADXS could easily double, triple, perhaps even quadruple, and still be UNDERVALUED.
If Sunshine Heart quintupled on a 6M share float, imagine how ADXS will trade if it catches momentum.
We think that ADXS could soar as
- near term data is released,
- FDA approves orphan drug designations for Company’s head & neck and cervical cancer drugs,
- a licensing or partnership deal is struck, and
- the Company uplists to the NASDAQ or NYSE MKT.
ADXS broke resistance on Thursday and is set for a higher move on Friday. Watch closely.
Happy Investing
PennyStockHaven Staff
About Advaxis :
Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The companys platform technology generates an immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor.
An affiliate of PennyStockHaven.com expects to receive twenty thousand dollars per month for providing consulting and advisory services to Advaxis. The affiliate may also receive up to two hundred thousand restricted shares in the company in the future. This compensation may affect the objectivity of our profile of the company. You should do your own homework and consult an investment professional before making any investment decisions. Read our full disclaimer here.